Trianni and Antibody Solutions jointly announced today that Antibody Solutions has entered into a license agreement with TRIANNI for use of The Trianni Mouse, a fully humanized transgenic mouse platform, to support its therapeutic antibody discovery programs.
"We're thrilled to take our partnership with Antibody Solutions to the next level through this agreement," said David Meininger, Ph.D., M.B.A., Chief Business Officer of TRIANNI. "We're confident that their demonstrated ability to leverage the power of The Trianni Mouse will translate to compelling new therapeutic leads."
"We have seen excellent outcomes using The Trianni Mouse in our contract research efforts for other Trianni partners," said John S. Kenney, Ph.D., President of Antibody Solutions. "We look forward to using The Trianni Mouse to advance our in-house discovery efforts and further improve our therapeutic antibody discovery platform."
No financial details were disclosed.